Atria Investments Inc Sells 10,865 Shares of AbbVie Inc. $ABBV

Atria Investments Inc decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 6.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 167,508 shares of the company’s stock after selling 10,865 shares during the period. Atria Investments Inc’s holdings in AbbVie were worth $38,785,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ABBV. CBIZ Investment Advisory Services LLC lifted its stake in shares of AbbVie by 10.2% in the 3rd quarter. CBIZ Investment Advisory Services LLC now owns 1,020 shares of the company’s stock valued at $236,000 after purchasing an additional 94 shares during the last quarter. Illinois Municipal Retirement Fund raised its holdings in AbbVie by 12.0% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 184,806 shares of the company’s stock valued at $42,790,000 after buying an additional 19,779 shares during the period. ICW Investment Advisors LLC lifted its position in AbbVie by 2.7% in the third quarter. ICW Investment Advisors LLC now owns 24,897 shares of the company’s stock worth $5,765,000 after buying an additional 665 shares during the last quarter. Echo45 Advisors LLC purchased a new position in AbbVie during the third quarter worth $259,000. Finally, Wedbush Securities Inc. increased its position in AbbVie by 1.0% during the third quarter. Wedbush Securities Inc. now owns 77,950 shares of the company’s stock valued at $18,048,000 after acquiring an additional 747 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on ABBV shares. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Evercore dropped their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. UBS Group reduced their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. The Goldman Sachs Group reissued a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research note on Wednesday, January 28th. Finally, DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research report on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Stock Down 0.8%

Shares of ABBV opened at $220.74 on Thursday. The company has a 50 day moving average of $223.47 and a two-hundred day moving average of $220.29. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a market cap of $390.12 billion, a price-to-earnings ratio of 93.53, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive: AbbVie’s real‑world PHASES migraine study could expand uptake for ubrogepant (an oral migraine treatment), improving its competitive positioning in migraine care and incremental revenue potential. AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
• Positive Sentiment: Positive: AbbVie updated its Phase 2 elezanumab study in acute cervical spinal cord injury — any favorable signals in neuroscience would bolster the pipeline and longer‑term growth optionality beyond immunology and aesthetics. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
• Neutral Sentiment: Neutral: Analyst coverage is shifting — some upgrades/notes frame AbbVie as a stronger value/growth combination given Rinvoq and Skyrizi momentum, which supports the longer‑term revenue thesis but may be priced in. How Recent Analyst Shifts Are Reframing AbbVie (ABBV) And Its Valuation Story
• Neutral Sentiment: Neutral: Research/commentary expects 2026 top‑line growth from Rinvoq and Skyrizi (offsetting Humira erosion); these projections support consensus revenue targets but leave sensitivity to execution and pricing. Here’s What Will Drive AbbVie’s Top-line Growth in 2026
• Neutral Sentiment: Neutral: Coverage highlighting AbbVie as a value/attractive income stock (Zacks, Seeking Alpha mentions) can support demand from income‑oriented investors even as valuation debates continue. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Negative Sentiment: Negative: The big near‑term headwind is CMS selecting Botox for price negotiation under the Inflation Reduction Act; AbbVie filed suit against HHS challenging the move. If price controls are upheld, Botox revenue and pricing could be materially affected; the lawsuit increases regulatory uncertainty and likely pressured shares. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Negative: Reports that AbbVie is reshaping U.S. operations with Medicaid concessions and broader pricing/alignment moves (including commentary about large domestic manufacturing deals) suggest margin and access tradeoffs; these actions can depress near‑term profitability even if they support market access. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.